Lilly pres Deirdre Connelly defects to GSK

Share this article:
Deirdre Connelly
Deirdre Connelly

In joint company statements today, GlaxoSmithKline and Lilly announced that Deirdre Connelly has resigned as president of US operations at Lilly, to become president, North American pharmaceuticals, at GlaxoSmithKline. Connelly will begin her new role at GSK on February 9, 2009.

In the statement, GSK CEO Andrew Witty said Connelly is “somebody who truly understands the needs of patients and our customers and can drive the efforts we are making to reshape this business and improve future growth.” Connelly had led Lilly's US operations since 2005.

Lilly, in turn, promoted Enrique Conterno, currently senior vice president of healthcare professional markets, to president, effective immediately. Conterno will report to Bryce Carmine, EVP of global marketing and sales.

Conterno “understands the complexities of the US marketplace, he has stressed the need to accelerate the transformation that is under way at this company, and he is focused on the needs of the patients we serve,” said John Lechleiter, Lilly's chairman, president and CEO, in a statement.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...